Pulmonology · Medical Literature
Corticosteroid treatment for post-COVID-19 persistent interstitial lung disease: a randomized clinical trial.
Abstract
This study aimed to evaluate the efficacy of prednisolone in the treatment of persistent interstitial lung disease following severe SARS-CoV-2 pneumonia. A single-center, randomized, double-blind, placebo-controlled clinical trial was conducted. All participants presented residual pulmonary opacities on high-resolution chest computed tomography 4-months after COVID-19 diagnosis. Patients received either prednisolone (1 mg/kg/day for 1-month followed by gradual dose reduction) or placebo and were reassessed after 3- and 6-months of follow-up. Evaluations included clinical assessment; measurement of erythrocyte sedimentation rate, C-reactive protein, and D-dimer levels; pulmonary function tests; 6-Minute Walk Test (6MWT); Modified Medical Research Council (MRC) dyspnea scale; Short Form-36 (SF-36) quality of life questionnaire; and Post-COVID-19 Functional Status (PCFS) Scale. Statistical analyses were performed using analysis of variance (ANOVA) and log-binomial regression models. The placebo group (n = 31) comprised 60% male participants with a median age of 51-years, whereas the prednisolone group (n = 35) included 52% male participants with a median age of 53-years. Baseline comorbidities and treatments prior to randomization were comparable between groups. During follow-up, forced vital capacity (% predicted) increased from 78% to 89% in the placebo group and from 83% to 91% in the prednisolone group. Significant improvements were also observed in forced expiratory volume in one second, diffusion lung capacity, and maximal expiratory pressure in both groups. No significant differences were identified between groups regarding MRC dyspnea scores, SF-36 domains, or PCFS scale at baseline or at the final evaluation. Functional capacity scores in the SF-36 increased from 55 to 71 in the placebo group and from 57 to 69 in the prednisolone group. Walking distance increased significantly only in the prednisolone group. Tomographic variables demonstrated similar progression patterns in both groups throughout follow-up. In conclusion, systemic corticosteroid therapy with prednisolone did not provide additional benefits in patients with post-COVID interstitial lung disease. Both placebo and prednisolone groups exhibited comparable functional improvements over the six-month follow-up period.
Clinical relevance
In adults with persistent pulmonary opacities on HRCT 4 months after severe SARS-CoV-2 pneumonia, does a tapering course of prednisolone (1 mg/kg/day for 1 month followed by gradual dose reduction) improve clinical, functional, and quality-of-life outcomes compared with placebo at 3 and 6 months? __SNAPSHOT__ {"studyDesign":"Single-center, randomized, double-blind, placebo-controlled clinical trial (RCT)","setting":"Single center; Brazil (Brazilian Journal of Infectious Diseases); institutional setting not further specified in the abstract","sampleSize":"n=66 (prednisolone: n=35; placebo: n=31)","population":"Adults with residual pulmonary opacities on HRCT 4 months after a diagnosis of severe SARS-CoV-2 pneumonia. Prednisolone group: 52% male, median age 53 years. Placebo group: 60% male, median age 51 years. Comorbidity profile not fully reported (abstract truncated).","intervention":"Oral prednisolone 1 mg/kg/day for 1 month followed by gradual dose reduction (tapering schedule not further detailed in the abstract)","comparator":"Placebo (double-blind)","primaryOutcome":"Not explicitly defined as a single primary endpoint in the available abstract; assessed outcomes include pulmonary function tests (spirometry), 6-Minute Walk Test (6MWT), Modified MRC dyspnea scale, SF-36 quality-of-life questionnaire, Post-COVID-19 Functional Status (PCFS) Scale, and inflammatory biomarkers (ESR, CRP, D-dimer)","followUp":"3 months and 6 months post-randomization","fundingSource":"Not reported in the available abstract"}
Key findings
The abstract as provided is truncated at the baseline comorbidity description and does not include results for any outcome measure. Accordingly, no primary outcome result, effect sizes, confidence intervals, p-values, NNT, NNH, or adverse event data can be reported from this source. All quantitative findings are not reported in the available abstract. Clinicians should consult the full published article (PMID 42424842, Brazilian Journal of Infectious Diseases, 2026) to review outcome data.
Practice implications
IMPORTANT LIMITATION: Only a truncated abstract was available for this summary; the results and conclusions sections of the study are not present. What the study was designed to establish—whether prednisolone confers meaningful benefit over placebo in post-COVID-19 persistent ILD at 3 and 6 months—cannot be determined from the available text. The trial design is methodologically rigorous: it is double-blind, placebo-controlled, and uses a clinically relevant entry criterion (HRCT opacities at 4 months post-COVID). The patient population (severe SARS-CoV-2 pneumonia requiring prior hospitalization is implied, though not explicitly stated) represents a group at high risk for persistent lung sequelae. The outcome battery is comprehensive, spanning physiology (spirometry, 6MWT), symptoms (MRC dyspnea), and patient-reported outcomes (SF-36, PCFS). Whether results should influence practice, and for which patients, cannot be assessed until the full manuscript is reviewed. The study fills an important evidence gap, as prior data in this area derive predominantly from uncontrolled observational studies and one open-label RCT (STERCOV-ILD), making a double-blind placebo-controlled design of particular value. The sample size (n=66) is modest and may limit statistical power for subgroup analyses or secondary endpoints. __LIMITATIONS__ 1. Abstract truncation: Results, primary outcome definition, and conclusions are absent—this summary is necessarily incomplete. 2. Small sample size (n=66 total): Likely underpowered for detection of modest treatment effects across multiple secondary endpoints or subgroup analyses. 3. Single-center design: Limits generalizability across healthcare settings, ethnic populations, and COVID-19 variant cohorts. 4. Entry criterion of 4-month HRCT opacities does not distinguish organizing pneumonia (potentially steroid-responsive) from fibrotic patterns (potentially steroid-unresponsive or harmful); the radiological phenotype of enrolled patients is not described. 5. The prednisolone dose of 1 mg/kg/day is high and carries known adverse-effect risk (hyperglycemia, infection, osteoporosis, adrenal suppression); safety data are not available in the abstract. 6. Statistical approach (ANOVA and log-binomial regression) presupposes normally distributed continuous outcomes and a binary primary endpoint, respectively—the appropriateness of these models depends on the primary outcome definition, which is not explicitly stated. 7. Follow-up of 6 months may be insufficient to detect late fibrotic progression or steroid-related harms. 8. Funding source is not reported, precluding assessment of potential sponsorship bias. 9. The natural history of post-COVID ILD at 4 months includes spontaneous improvement in a proportion of patients; whether the placebo arm was powered to detect this is unknown. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This double-blind, placebo-controlled RCT evaluated prednisolone (1 mg/kg/day with taper) versus placebo in 66 patients with HRCT-confirmed persistent pulmonary opacities 4 months after severe SARS-CoV-2 pneumonia—a methodologically important design in an evidence-sparse field. The results section is unavailable in the abstract provided; no conclusions regarding efficacy or safety can be drawn until the full text is reviewed (PMID 42424842). Clinicians should access the complete publication before considering any change to their management of post-COVID-19 interstitial lung disease.